A UCSF-spun startup backed by Andreessen Horowitz and Y Combinator announced today that it has closed a $9.1 million seed round to advance a genetically engineered virus into its first human clinical ...

Glioblastoma (GBM) is an aggressive type of brain cancer that is known to be very difficult to treat. One reason why this type of cancer is often resistant to available treatments is that it is ...

"Getting my diagnosis was an interesting journey," Becca Valle tells PEOPLE Courtesy of Becca Valle A woman, who thought she was suffering from "chronic migraines," ended up getting diagnosed with a ...

Glioblastoma patients, long shut out from immunotherapies that have transformed patient care in other cancers, could finally benefit from a new treatment option. Boston cancer researchers have found ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Nick Leschly, the CEO who became synonymous ...

Kyle Donahue, who enrolled in a clinical trial at Brigham and Women's Hospital, is now a five-year survivor of brain cancer. Kyle Donahue, who was given months to live after receiving a diagnosis of ...

Fifteen years ago, Jinan Behnan, PhD, was a graduate student at Lund University in Lund, Sweden, performing a routine dissection that would stay with her for more than a decade. Jinan Behnan, PhD ...

Exosome-based treatment for GBM has received FDA orphan drug designation, indicating its potential in treating this aggressive CNS tumor. Exousia AI's technology uses exosomes to deliver therapeutics ...

(A) The heatmap showing the differential expression of the Wnt proteins and the Wnt target genes between the GTEx cortex (n = 199) and TCGA-GBM (n = 173) datasets. (B) The spatial transcriptomic data ...

(A) Homogenous time-resolved fluorescence (HTRF) assay screening schematic. (B) HTRF assay screening compounds. (C) HTRF assay showed that the effect of FX1, BI-3802, and YK01 blocked the interaction ...

Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression GBM represents an annual market opportunity of $3 to $5 billion USD with an ...

Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...